Type II collagen-reactive T cell receptor-MHC II complex (CII-TCR-MHC II complex)

The Type II collagen-reactive T cell receptor (TCR) and its associated antigen-presenting cell (APC) complexes, specifically the MHC class II-peptide complex, represent a critical immunological synapse in the pathogenesis of rheumatoid arthritis. Type II collagen (CII) is the primary structural protein of articular cartilage, and its recognition by autoreactive T cells is a hallmark of both human rheumatoid arthritis and the collagen-induced arthritis (CIA) animal model. In the gut-associated lymphoid tissue (GALT), the interaction between CII-derived peptides presented by MHC II (such as HLA-DR4) and specific TCRs can lead to the induction of oral tolerance, a state of peripheral immune unresponsiveness. This mechanism is leveraged in therapeutic strategies aiming to suppress systemic autoimmunity by promoting the differentiation of regulatory T cells (Tregs) that secrete anti-inflammatory cytokines like IL-10 and TGF-beta. Targeting this complex involves either blocking the pathogenic activation of effector T cells or harnessing the GALT's natural tolerogenic environment to treat chronic inflammatory joint diseases.

Other names

CII-specific T cell receptorType II collagen-specific TCR-HLA-DR complexCollagen II-reactive TCRCII-peptide-MHC complex

Modulation of T cell activation by interfering with the TCR-MHC II-peptide interaction or inducing peripheral tolerance through regulatory T cell expansion.